The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study.
Dat NgoJason ChenJose TinajeroAhmed AribiShukaib ArslanGuido MarcucciRyotaro NakamuraMonzr M Al MalkiStephen J FormanSanjeet DadwalHaris AliPublished in: Stem cell research & therapy (2023)
This study reports the incidence of chronic graft versus host disease (GvHD) in allogeneic hematopoietic stem cell transplant (alloHCT) recipients who received SARS-CoV2 vaccination. The overall rates of new and worsening chronic GvHD combined were 14%, with median time from vaccination to GVHD being approximately three to four weeks. A majority of the cases were of mild to moderate severity and primarily localized to either the skin, mouth, or joints. Prior chronic GVHD and recent transplant were associated with higher GVHD rates following COVID-19 vaccination. More prospective studies are needed to provide a definitive mechanism for the impact of SARS-CoV2 vaccination on alloHCT patients.
Keyphrases
- hematopoietic stem cell
- sars cov
- allogeneic hematopoietic stem cell transplantation
- respiratory syndrome coronavirus
- end stage renal disease
- risk factors
- stem cell transplantation
- ejection fraction
- chronic kidney disease
- newly diagnosed
- coronavirus disease
- bone marrow
- acute lymphoblastic leukemia
- acute myeloid leukemia
- radiation therapy
- squamous cell carcinoma
- drug induced
- peritoneal dialysis
- rectal cancer
- kidney transplantation